Drug Profile
LY 2928057
Alternative Names: Anti-ferroportin antibody; LY-2928057Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antianaemics; Antibodies; Monoclonal antibodies
- Mechanism of Action Cation transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anaemia
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for phase-I development in Anaemia(In volunteers) in Singapore (IV, Infusion)
- 03 Dec 2016 Adverse event, pharmacodynamics and pharmacokinetics data from a clinical trial in Anaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
- 21 Apr 2014 Phase-II clinical trials in Anaemia in USA (IV)